Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
In this episode, we discuss: The controversial discussion of GLP-1 agonists like Ozempic, weighing the pros and cons of these new drugs in treating obesity and metabolic crises (3:34) Challenging the notion of treating obesity with drugs like Ozempic (10:35) An unsettling revelation about the push for using Ozempic in children (12:04) Digging deeper into GLP-1 research and some of the benefits (32:51) Why are children being born metabolically challenged
Le Thuc O, Stobbe K, Cansell C, Nahon JL, Blondeau N, Rovre C (2017) Hypothalamic inflammation and Energy Balance Disruptions: spotlight on Chemokines
Patients in Ro's study lost an average of 16.6% of their body weight over 68 weeks
Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with Type 2 diabetes
After four weeks, she increased her dose to 0.50 mg, following the recommended titration schedule
US$ 22.24
US$ 26.65
US$ 29.05
US$ 20.67
